Method and kit for jointly detecting various antibiotics in sample to be detected

Through the liquid chromatography-mass spectrometry detection method, combined with isotope internal standards, the problem of difficulty in monitoring multiple antibiotic concentrations at the same time in the prior art is solved, and efficient and accurate antibiotic monitoring is achieved, reducing detection costs.

CN119000955AInactive Publication Date: 2024-11-22SECOND MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL

Patent Information

Application Number
CN202411385221.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-30
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to accurately monitor the concentration of multiple antibiotics in the human body at the same time, including antifungal drugs, and the detection efficiency is low and the cost is high.

Method used

The liquid chromatography-mass spectrometry detection method was used to determine the content of each antibiotic in the sample to be tested, including vancomycin, meropenem, and the preparation of the sample to be tested, and the calibration curve and quality control sample were prepared, combined with isotope internal standards. Concentrations of levofloxacin, moxifloxacin, linezolid, fluconazole, cefoperazone, piperacillin, voriconazole, daptomycin.

Benefits of technology

Accurate monitoring of a variety of antibiotics is achieved, the detection results are linear within the test concentration range, with high precision, low signal crossover contribution, reliable detection results and relatively low cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119000955A_ABST
    Figure CN119000955A_ABST
Patent Text Reader

Abstract

The invention relates to a method for jointly detecting various antibiotics and viruses in a sample, which comprises the following steps: (1) preparing a calibration curve and a quality control sample; (2) treating an in-vitro serum sample to be detected; (3) carrying out liquid chromatography separation-mass spectrometry detection on the sample; and (4) determining the content of each antibiotic in the to-be-detected sample based on a liquid chromatography separation-mass spectrometry detection result, compared with the prior art, the method provided by the invention has the advantages that the detected data volume is more, the cost and time are reduced, and meanwhile, the reliability of the detection method is shown from different aspects, including detection limit, accuracy, inter-batch and intra-batch precision, residue and other information.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection, and in particular to a method and a kit for jointly detecting multiple antibiotics in a sample to be detected. Background Art

[0002] Antibiotics, also known as antimicrobials, refer to a class of secondary metabolites produced by microorganisms (including bacteria, fungi, and actinomycetes) or higher animals and plants in their life processes that have anti-pathogen or other activities, and are chemical substances that can interfere with the developmental functions of other living cells. The use of antibiotics has had a huge impact on medicine, and is a large amount of anti-infective drugs used in hospitals on a daily basis. However, the abuse of antibiotics is quite common worldwide. Patients will use one or more antibiotics to prevent infection when they are sick. At the same time, since antibiotics are also used for poultry and aquatic organisms during the breeding process, people will accumulate antibiotics in the human body when they eat foods containing antibiotics. When the amount of antibiotics accumulated in the human body increases to a certain amount, it will affect the normal physiological functions of the human body and even lead to the generation and mutation of drug-resistant bacteria, thereby making some commonly used antibiotics ineffective and giving rise to super bacteria that cannot be killed by antibiotics. Therefore, various countries are paying more and more attention to the monitoring of antibiotics. The rational use of antibiotics and avoidance of antibiotic abuse are of great significance to the prevention and treatment of diseases.

[0003] Therapeutic drug monitoring (TDM) based on antibiotic concentration levels has been proposed to optimize exposure. Immunoassays are widely used as a method to implement TDM. However, they are often affected by human antibodies in vivo, lack specificity and accuracy, and have high detection costs. High-performance liquid chromatography (HPLC) detection instruments are reliable, but the detection efficiency is low and the detection time is long. As a relatively new technology, liquid chromatography tandem mass spectrometry (LC-MS / MS) method overcomes the shortcomings of long detection cycle and large sample collection volume, and has been widely used in laboratory monitoring. However, most LC-MS / MS methods can only detect a small number of antibiotics at the same time, and few can detect antifungal drugs.

[0004] Therefore, it is very important to accurately monitor the concentration levels of multiple antibiotics, including antifungal drugs, in the human body at one time. Summary of the invention

[0005] Purpose of the invention: To solve one of the technical problems in the above-mentioned related technologies.

[0006] Technical solution: A method for jointly detecting multiple antibiotics in a sample to be tested, including

[0007] The first step is the preparation of calibration curve and quality control samples, including preparation of stock solution, preparation of calibration curve and quality control products, and preparation of isotope internal standards.

[0008] The second step is to process the sample to be tested, wherein the sample to be tested is an in vitro serum sample;

[0009] In the third step, the samples were subjected to liquid chromatography separation-mass spectrometry detection;

[0010] The fourth step is to determine the content of each antibiotic in the sample to be tested based on the liquid chromatography separation-mass spectrometry detection result, and the antibiotics include vancomycin, meropenem, levofloxacin, moxifloxacin, linezolid, fluconazole, cefoperazone, piperacillin, voriconazole, and daptomycin;

[0011] In the liquid chromatography separation-mass spectrometry detection, the column temperature was 40°C; mobile phase A was 0.1% formic acid water, mobile phase B was 0.1% formic acid acetonitrile / methanol (1:1), flow rate was 0.5 mL / min, injection volume was 10 μL, sample chamber temperature was 8°C; elution program is shown in Table 1:

[0012] Table 1

[0013]

[0014]

[0015] The mass spectrometry conditions were: electrospray ionization mode, detection in positive ion mode; scanning mode: multiple reaction monitoring mode. The ion source parameters were as follows: capillary voltage 4 kV, vacuum interface temperature 115 °C, desolvation gas temperature 400 °C, nebulizer gas flow rate 1.5 L / min, desolvation gas flow rate 8 L / min, backflush gas flow rate 2 L / min; analyte ion pair parameters are shown in Table 2;

[0016] Table 2

[0017]

[0018] Further, the stock solution was prepared as follows: 10 target objects were weighed in a 50 mL centrifuge tube using a 1 / 100,000 balance, vancomycin weighed 21.05 mg, daptomycin weighed 40.82 mg, meropenem weighed 23.04 mg, linezolid weighed 4.02 mg, voriconazole weighed 4.01 mg, cefoperazone weighed 85.29 mg, piperacillin weighed 100 mg, levofloxacin weighed 8.24 mg, moxifloxacin weighed 4.58 mg, fluconazole weighed 10.02 mg, dissolved in 10 mL DMSO / methanol / water solution (v:v:v=1:10:9), and stored at -80°C.

[0019] Further, the calibration curve and quality control product preparation: the stock solution and the drug-free blank blood

[0020] The blank serum was mixed so that the highest concentrations of vancomycin, meropenem, fluconazole, cefoperazone, linezolid, levofloxacin, piperacillin, moxifloxacin, voriconazole and daptomycin in the working calibration curve were 99.99 mg / L, 99.99 mg / L, 49.10 mg / L, 400.01 mg / L, 19.90 mg / L, 40.38 mg / L, 480.50 mg / L, 22.67 mg / L, 19.65 mg / L and 200.02 mg / L respectively; the other concentration points of the calibration curve were obtained by mixing the highest concentration with blank serum and gradient dilution;

[0021] The quality control product is prepared as follows: the concentration of vancomycin is 3.81mg / L-35.19mg / L; the concentration of meropenem is 4.46mg / L-40.21mg / L; the concentration of fluconazole is 1.38mg / L-13.44mg / L; the concentration of cefoperazone is 15.26mg / L-146.72mg / L; the concentration of linezolid is 0.96mg / L-8.6mg / L; the concentration of levofloxacin is 1.14mg / L-10.57mg / L; the concentration of piperacillin is 13.49mg / L-125.85mg / L; the concentration of moxifloxacin is 0.79mg / L-7.4mg / L; the concentration of voriconazole is 0.72mg / L-7.21mg / L; the concentration of daptomycin is 10.56mg / L-85.58mg / L

[0022] To ensure the integrity of the serum at the highest concentration point of the calibration curve and during the preparation of quality controls, the final volume of the total content of water, methanol, and DMSO was kept ≤10%.

[0023] Further, the preparation of the isotope internal standard: the stock solution concentration of the internal standard voriconazole-[13C2, d3], meropenem-[d6], linezolid-[d3], piperacillin-[d5], levofloxacin-[d3] is 1 mg / mL, the stock solution concentration of moxifloxacin-[d4] is 2 mg / mL, and the stock solution concentration of norvancomycin is 40 mg / mL. The concentration of voriconazole-[13C2, d3] and linezolid-[d3] in the internal standard working solution is 0.1 mg / mL, the concentration of meropenem-[d6], piperacillin-[d5], levofloxacin-[d3], moxifloxacin-[d4] is 0.2 mg / mL, and the concentration of norvancomycin is 4 mg / mL, which are mixed in a methanol solution and stored at -80°C before use.

[0024] Further, the sample processing is as follows: each point of the serum calibration curve and the low, medium and high level quality control products are mixed with the internal standard working solution, the test tube is vortexed and centrifuged, the supernatant is diluted with 0.1% formic acid water, and then the sample is injected into LC-MS / MS to monitor the reaction of all analytes.

[0025] Beneficial effects:

[0026] 1. The test results are linear within the test concentration range.

[0027] 2. Analysis of the precision data showed that the intra-batch precision of the three-level quality control products for each analyte was ≤10%, and most of the inter-batch precision of the three-level quality control products for each analyte was also ≤10%, except for the inter-batch precision of the low-concentration moxifloxacin quality control product, which was 11%.

[0028] 3. Signal crossover contribution: The crossover signal contribution of the naturally occurring isotope transition of each analyte at the upper limit of quantitation in the selected internal standard MRM ion pair is <5% of the set internal standard concentration signal. No analyte signal interference in the selected internal standard solution.

[0029] 4. The evaluation was performed by first testing the highest calibration curve concentration and then testing the double blank serum extract. Follow-up test results showed that the responses of the ten analytes in the blank samples did not exceed 10% of the quantification limit response of the analytes, and the residual proportion of vancomycin was 0.00%. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Mass spectrum of vancomycin single standard solution

[0031] Figure 2 Mass spectrum of meropenem single standard solution

[0032] Figure 3 Mass spectrum of cefoperazone single standard solution analysis

[0033] Figure 4 Mass spectrum of moxifloxacin single standard solution

[0034] Figure 5 Mass spectrum of levofloxacin single standard solution

[0035] Figure 6 Mass spectrum of fluconazole single standard solution

[0036] Figure 7 Mass spectrum of voriconazole single standard solution

[0037] Figure 8 Mass spectrum of linezolid single standard solution

[0038] Fig. 9 Mass spectrum of piperacillin single standard solution

[0039] Fig.10 Mass spectrum of daptomycin single standard solution

[0040] Fig.11 Total ion current (TIC) of analytes

[0041] Fig.12 Meropenem linear detection curve

[0042] Fig.13 Vancomycin linear detection curve

[0043] Fig.14 Levofloxacin linear detection curve

[0044] Fig.15 Moxifloxacin linear detection curve

[0045] Fig.16 Fluconazole linear detection curve

[0046] Fig.17 Voriconazole linear detection curve

[0047] Fig.18 Linear detection curve of cefoperazone

[0048] Fig.19 Linear detection curve of linezolid

[0049] Fig. 20 Piperacillin linear detection curve

[0050] Fig.21 Daptomycin linear detection curve

[0051] Fig. 22 Levofloxacin chromatogram of patient sample

[0052] Fig.23 Moxifloxacin chromatogram of patient sample

[0053] Fig.24 Spectra of cefoperazone, fluconazole, and linezolid in patient samples

[0054] Fig.25 Chromatograms of vancomycin and daptomycin in patient samples

[0055] Fig.26 Chromatograms of linezolid, piperacillin, and voriconazole in patient samples

[0056] Fig. 27 Chromatograms of meropenem and linezolid in patient samples DETAILED DESCRIPTION

[0057] 1. Selection of chemicals and reagents

[0058] Linezolid, fluconazole, voriconazole, levofloxacin, moxifloxacin, vancomycin, and daptomycin were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., piperacillin, cefoperazone, and meropenem were purchased from the China Food and Drug Inspection Institutes, and the reagents used in the experiment (LC–MS grade methanol and acetonitrile were purchased from Thermo Fisher Scientific, and formic acid was purchased from Sigma-Aldrich) were purchased from the China Food and Drug Inspection Institutes.

[0059] Internal standards voriconazole-[13C2,d3], meropenem-[d6], linezolid-[d3], piperacillin-[d5] were purchased from Shimadzu (Shanghai) Laboratory Equipment Co., Ltd., levofloxacin-[d3] was purchased from Toronto Research Chemicals (TRC), Canada, and moxifloxacin-[d4] was purchased from Nanjing Haolu Biotechnology Co., Ltd. Norvancomycin was used as the internal standard of vancomycin and was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. Detailed information is shown in Table 3

[0060] Table 3

[0061] Serial number Chinese name English name Manufacturer purity 1 Piperacillin Piperacillin China Food and Drug Inspection Institute 96.1% 2 Cefoperazone Cefoperazone China Food and Drug Inspection Institute 93.8% 3 Linezolid Linezolid aladdin ≥99% 4 Meropenem Meropenem China Food and Drug Inspection Institute 86.8% 5 Fluconazole Fluconazol aladdin ≥98% 6 Voriconazole Voriconazole aladdin ≥98% 7 Levofloxacin Levofloxacin aladdin ≥98% 8 Moxifloxacin Moxifloxacin aladdin ≥99% 9 Vancomycin Vancomycin aladdin ≥95% 10 Daptomycin Daptomycin aladdin ≥98%

[0062] 2. Instrument and liquid quality conditions

[0063] The LC-MS instrument (LMSQ1000, Shenzhen BGI Biomedical Engineering Co., Ltd., China) includes a liquid chromatography system and a mass spectrometry system.

[0064] 2.1 Chromatographic conditions

[0065] The chromatographic column was BGIU Column-U02 (2.1x50mm, 3μm), the column temperature was 40°C, the mobile phase A was 0.1% formic acid in water, the mobile phase B was 0.1% formic acid in acetonitrile / methanol (1:1), the flow rate was 0.5mL / min, the injection volume was 10μL, and the sample chamber temperature was 8°C. The elution program is shown in Table 1:

[0066] 2.2 Mass spectrometry conditions

[0067] Electrospray ionization was used, and detection was performed in positive ion mode; scanning mode: multiple reaction monitoring mode. The ion source parameters were as follows: capillary voltage 4 kV, vacuum interface temperature 115 °C, desolvation gas temperature 400 °C, nebulizer gas flow rate 1.5 L / min, desolvation gas flow rate 8 L / min, backflush gas flow rate 2 L / min. The optimized analyte ion pair parameters are shown in Table 2, and the mass spectra of each analyte and the total ion map of 10 analytes are shown in Figures 1 to 11 The sample chromatograms of some patients are shown in Figure 22 to Figure 27 .

[0068] 3. Preparation of Calibration Curve and Quality Control Samples

[0069] Preparation of stock solution: Use a 1 / 100,000 balance to weigh 10 target substances in a 50 mL centrifuge tube, including 21.05 mg of vancomycin, 40.82 mg of daptomycin, 23.04 mg of meropenem, 4.02 mg of linezolid, 4.01 mg of voriconazole, 85.29 mg of cefoperazone, 100 mg of piperacillin, 8.24 mg of levofloxacin, 4.58 mg of moxifloxacin, and 10.02 mg of fluconazole. Dissolve in 10 mL of DMSO / methanol / water solution (v:v:v=1:10:9) and store at -80°C.

[0070] Preparation of calibration curve and quality control products: the stock solution was mixed with drug-free blank serum, so that the highest concentrations of vancomycin, meropenem, fluconazole, cefoperazone, linezolid, levofloxacin, piperacillin, moxifloxacin, voriconazole, and daptomycin in the working calibration curve were 99.99 mg / L, 99.99 mg / L, 49.10 mg / L, 400.01 mg / L, 19.90 mg / L, 40.38 mg / L, 480.50 mg / L, 22.67 mg / L, 19.65 mg / L, and 200.02 mg / L, respectively. The other concentration points of the calibration curve were obtained by mixing the highest concentration with blank serum and gradient dilution. There are three concentration levels of quality control products, namely low, medium, and high. The three levels of vancomycin concentrations were 3.81 mg / L, 16.15 mg / L, and 35.19 mg / L; the three levels of meropenem concentrations were 4.46 mg / L, 20.58 mg / L, and 40.21 mg / L; the three levels of fluconazole concentrations were 1.38 mg / L, 6.32 mg / L, and 13.44 mg / L; the three levels of cefoperazone concentrations were 15.26 mg / L, 71.19 mg / L, and 146.72 mg / L; the three levels of linezolid concentrations were 0.96 mg / L, 4 mg / L, and 8.6 mg / L; The three levels of floxacin are 1.14 mg / L, 4.89 mg / L, 10.57 mg / L; the three levels of piperacillin are 13.49 mg / L, 64.3 mg / L, 125.85 mg / L; the three levels of moxifloxacin are 0.79 mg / L, 3.61 mg / L, 7.4 mg / L; the three levels of voriconazole are 0.72 mg / L, 3.41 mg / L, 7.21 mg / L; the three levels of daptomycin are 10.56 mg / L, 44.19 mg / L, 85.58 mg / L. At the highest concentration point of the calibration curve and during the preparation of quality control products, in order to ensure the integrity of the serum, the final volume of the total content of water, methanol, and DMSO was kept at ≤10%.

[0071] Preparation of isotope internal standards: The stock solution concentration of internal standards voriconazole-[13C2,d3], meropenem-[d6], linezolid-[d3], piperacillin-[d5], levofloxacin-[d3] is 1 mg / mL, the stock solution concentration of moxifloxacin-[d4] is 2 mg / mL, and the stock solution concentration of norvancomycin is 40 mg / mL. The concentration of voriconazole-[13C2,d3], linezolid-[d3] is 0.1 mg / mL, the concentration of meropenem-[d6], piperacillin-[d5], levofloxacin-[d3], moxifloxacin-[d4] is 0.2 mg / mL, and the concentration of norvancomycin is 4 mg / mL in the internal standard working solution. They are mixed in methanol solution and stored at -80°C before use.

[0072] 4. Sample pre-treatment process

[0073] Each point of the serum calibration curve and the low, medium, and high level quality control samples (40 μL) were mixed with the internal standard working solution (160 μL), the tubes were vortexed (2 min), centrifuged (10 min, 14000 × g), the supernatant was diluted with 0.1% formic acid water (1 / 5), and then the samples were injected into the LC-MS / MS. For each calibration curve, a double blank sample containing neither analyte nor internal standard, and a calf serum (blank matrix sample mixed with internal standard) were prepared.

[0074] 5. Verification Scheme

[0075] The development and validation of this experimental method was based on NATA guidelines, and the evaluation included linearity, accuracy, precision, specificity, sensitivity, carryover, and stability.

[0076] 5.1 Linearity

[0077] Ten concentrations of drug were added to drug-free serum to form a calibration curve, and the calibration curve was fitted by the peak area ratio of each analyte to its corresponding internal standard and the labeled concentration of the analyte, weighted 1 / x2. The acceptance criteria for each calibration curve point was set to ±15% of the spike concentration, and the LLOQ allowed ±20%. The correlation coefficient (r) was set to ≥0.990.

[0078] 5.2 Accuracy and precision

[0079] QC analysis was performed at 3 concentrations for each analyte, 10 times per day for a total of 3 days. Intra-day and inter-day precision were evaluated by coefficient of variation (CV% = 100*standard deviation / mean) and accuracy (mean assay concentration / spiked concentration*100). The acceptance criteria for the coefficient of variation of each level of QC were set to ≤15%, and the acceptance criteria for the accuracy of each level of QC were set to ±15% of the spiked concentration. The limit of detection (LOD) was defined as the lowest concentration at which the peak height was 3 times the height of the blank sample.

[0080] 5.3 Specificity and selectivity

[0081] Cross-signal contribution. The cross-signal contribution between the analyte and the isotopic internal standard comes from naturally occurring isotopes and isotopes of impure purity. Individual analytes are prepared in pure solution, the concentration is set to the upper limit of quantitation, the internal standard concentration is 1 mg / L, the analytes and internal standards are injected into the LC-MS / MS separately, and the response of all analytes is monitored simultaneously. Any peak observed at a specific retention time (Rt) and MRM channel, except for the analyte injected into the mass spectrometer, is considered a cross-signal contribution. The acceptance criteria are set as the response of the cross-signal ≤ 20% of the lower limit of quantitation and ≤ 5% of the selected internal standard signal.

[0082] 5.4 Matrix effect

[0083] Referring to the matrix effect experimental method in the "Guidelines for Validation of Quantitative Analysis Methods for Biological Samples" included in the "Pharmacopoeia of the People's Republic of China" (2020 Edition) (Part 4), at least 6 batches of blank matrix and standard blank serum matrix from different donors were used. For each batch of matrix, two concentration gradients of analytes were added. The peak area in the presence of matrix (measured by adding analytes and internal standards after extraction from blank matrix) was calculated, and the matrix factor of each analyte and internal standard was calculated by calculating the ratio of the peak area in the presence of matrix (measured by adding analytes and internal standards after extraction from blank matrix) to the corresponding peak area without matrix (pure solutions of analytes and internal standards). The matrix factor normalized by the internal standard is further calculated by dividing the matrix factor of the analyte by the matrix factor of the internal standard. The coefficient of variation of the internal standard normalized matrix factor calculated from 6 batches of matrix shall not be greater than 15%.

[0084] 5.5 Carryover

[0085] The evaluation was performed by testing the highest calibration curve concentration followed by double blank serum extracts. According to the guidelines, the acceptance criterion for carryover was that the blank response should not exceed 20% of the quantitation limit response of the analyte.

[0086] 5.6 Stability

[0087] The storage stability of fresh samples was evaluated by measuring the spike recovery of fresh spiked samples stored at three storage conditions (room temperature, 4°C, and -20°C) for 6 days. The stability of three freeze-thaw cycles of antimicrobial samples at three levels of concentration was evaluated (-20°C to RT). The upper limit of the stability evaluation time in the autosampler after sample extraction was set to 24 hours, and the evaluation standard was that if the test concentration was ±15% of the average concentration of the freshly prepared QC samples at the same concentration, the analyte was considered stable under this condition. The stability of all analytes in the stock solution lyophilized powder was evaluated at -80°C for up to 18 months. A stock solution lyophilized powder was taken from each stock solution lyophilized powder at 0, 3, 6, 9, 12, 15, and 18 months to prepare a concentration level QC for testing and compared with freshly prepared samples of the same concentration. The evaluation standard was that if the test concentration was ±15% of the average concentration of the freshly prepared QC samples at the same concentration, the analyte was considered stable under this condition.

[0088] 6. Results

[0089] 6.1 Linearity

[0090] The test results are linear within the test concentration range, see Figures 12 to 21 The concentration ranges are as follows: vancomycin and meropenem are 1.56 mg / L to 99.99 mg / L, fluconazole is 0.77 mg / L to 49.1 mg / L, cefoperazone is 6.25 mg / L to 400.01 mg / L, linezolid is 0.31 mg / L to 19.9 mg / L, levofloxacin is 0.63 mg / L to 40.38 mg / L, piperacillin is 7.51 mg / L to 480.5 mg / L, moxifloxacin is 0.35 mg / L to 22.67 mg / L, voriconazole is 0.31 mg / L to 19.65 mg / L, and daptomycin is 3.13 mg / L to 200.02 mg / L. The calibration curve information of each analyte is as follows, and the linear correlation coefficient r of the calibration curve of each analyte is ≥ 0.990. The summarized r values ​​are shown in Table 4.

[0091] Table 4

[0092] Analytes r-value Analytes r-value Vancomycin 0.9990 Voriconazole 0.9995 Meropenem 0.9998 Cefoperazone 0.9998 Levofloxacin 0.9993 Linezolid 0.9995 Moxifloxacin 0.9987 Piperacillin 0.9997 Fluconazole 0.9995 Daptomycin 0.9993

[0093] 6.2 Accuracy and precision

[0094] Precision and accuracy data are shown in the table below. Analysis of precision data showed that the intra-batch precision of the three-level quality control products for each analyte was ≤10%, and most of the inter-batch precision of the three-level quality control products for each analyte was also ≤10%, except for the inter-batch precision of the low-concentration quality control product of moxifloxacin, which was 11%. Analysis of accuracy data showed that the intra-batch accuracy of the three-level quality control products for each analyte was between 95% and 110%, and most of the inter-batch accuracy of the three-level quality control products for each analyte was between 95% and 110%, except for the inter-batch accuracy of the low-concentration quality control product of moxifloxacin, which was 111%. The accuracy of all levels of quality control products was within the set acceptance standard of ±15%. The LOQs of vancomycin, meropenem, fluconazole, cefoperazone, linezolid, levofloxacin, piperacillin, moxifloxacin, voriconazole, and daptomycin were 1.56 mg / L, 1.56 mg / L, 0.77 mg / L, 6.25 mg / L, 0.31 mg / L, 0.63 mg / L, 7.51 mg / L, 0.35 mg / L, 0.31 mg / L, and 3.13 mg / L, respectively. See Table 5 for details.

[0095] Table 5

[0096]

[0097]

[0098] 6.3 Specificity and selectivity

[0099] Signal crossover contribution. The crossover signal contribution of the naturally occurring isotopic transitions of each analyte at the upper limit of quantitation at the selected internal standard MRM transition is <5% of the signal of the set internal standard concentration. No analyte signal interference in the selected internal standard solution.

[0100] 6.4 Matrix effect

[0101] Seven batches of blank matrix and calf serum matrix from different donors were used, and two concentration gradients of analytes were added. The results after matrix factor normalization are shown in Tables 6-14. The coefficient of variation of matrix factors in the matrix (calf serum) analytes and clinical samples of this method is no more than 10%, which meets the requirements of the Chinese Pharmacopoeia, indicating that this method has no obvious matrix effect.

[0102] Table 6 Vancomycin matrix factor analysis results

[0103]

[0104]

[0105] Table 7 Results of analysis of meropenem matrix factors

[0106]

[0107]

[0108] Table 8 Fluconazole matrix factor analysis results

[0109]

[0110]

[0111]

[0112]

[0113] Table 9 Linezolid matrix factor analysis results

[0114]

[0115]

[0116] Table 10 Levofloxacin matrix factor analysis results

[0117]

[0118]

[0119] Table 11 Piperacillin matrix factor analysis results

[0120]

[0121]

[0122] Table 12 Moxifloxacin matrix factor analysis results

[0123]

[0124]

[0125] Table 13 Voriconazole matrix factor analysis results

[0126]

[0127] Table 14 Daptomycin matrix factor analysis results

[0128]

[0129]

[0130] Carryover

[0131] The evaluation was performed by first testing the highest calibration curve concentration and then testing the double blank serum extract. Following the test results, the responses of the ten analytes in the blank samples did not exceed 10% of the quantification limit response of the analytes, of which the residual ratio of vancomycin was 0.00%. The response ratios of each analyte are shown in Table 15.

[0132] Table 15

[0133]

[0134] Stability

[0135] Sample stability. Fresh samples were stored at room temperature, 4°C, and -20°C. By analyzing the data, it was found that, with fresh samples at the same concentration as the control, vancomycin, levofloxacin, linezolid, meropenem, moxifloxacin, cefoperazone, daptomycin, piperacillin, fluconazole, and voriconazole were stable at 4°C and -20°C for 6 days, with a deviation of ≤15% from the fresh samples. However, when stored at room temperature, meropenem and cefoperazone could only be stored for two days (deviation within two days ≤15%), and the other indicators could be stored for up to 6 days, as shown in Table 16.

[0136] Table 16

[0137]

[0138]

[0139] Freeze-thaw stability. After three freeze-thaw cycles, the three-level QC had a deviation of ≤15% from the freshly prepared QC of the same concentration. See Table 17 for details.

[0140] Table 17

[0141]

[0142]

[0143]

[0144] Stability after extraction. After extraction, the samples were stored in an automatic sampler (8°C). By analyzing the data, it was found that, with fresh samples at the same concentration as the control, the deviation from the fresh samples was ≤15% as the standard. Voriconazole, piperacillin, fluconazole, levofloxacin, and vancomycin could be stored in the automatic sampler for 24 hours, linezolid and cefoperazone could be stored for 11 hours, meropenem and moxifloxacin for 6 hours, and daptomycin for 13 hours. See Table 18 for details.

[0145] Table 18

[0146]

[0147] Stability of stock solution. One concentration level QC was prepared from one sample of stock solution lyophilized powder at 0, 3, 6, 9, 12, 15, and 18 months for testing and compared with freshly prepared samples of the same concentration. If the deviation between the tested concentration and the average concentration of the freshly prepared QC samples at the same concentration was ≤15%, it was proved that the analytes were stable when the stock solution lyophilized powder was stored at -80°C, as shown in Tables 19-21 for details.

[0148] Table 19

[0149]

[0150] Table 20

[0151]

[0152] Table 21

[0153]

[0154]

Claims

1. A method for jointly detecting multiple antibiotics in a sample to be tested, characterized in that: include The first step is the preparation of calibration curve and quality control samples, including preparation of stock solution, preparation of calibration curve and quality control products, and preparation of isotope internal standards. The second step is to process the sample to be tested, wherein the sample to be tested is an in vitro serum sample; In the third step, the samples were subjected to liquid chromatography separation-mass spectrometry detection; The fourth step is to determine the content of each antibiotic in the sample to be tested based on the liquid chromatography separation-mass spectrometry detection result, and the antibiotics include vancomycin, meropenem, levofloxacin, moxifloxacin, linezolid, fluconazole, cefoperazone, piperacillin, voriconazole, and daptomycin; In the liquid chromatography separation-mass spectrometry detection, the column temperature was 40°C; mobile phase A was 0.1% formic acid water, mobile phase B was 0.1% formic acid acetonitrile / methanol (1:1), flow rate was 0.5 mL / min, injection volume was 10 μL, sample chamber temperature was 8°C; elution program is shown in Table 1: Table 1 The mass spectrometry conditions were: electrospray ionization mode, detection in positive ion mode; scanning mode: multiple reaction monitoring mode. The ion source parameters were as follows: capillary voltage 4 kV, vacuum interface temperature 115 °C, desolvation gas temperature 400 °C, nebulizer gas flow rate 1.5 L / min, desolvation gas flow rate 8 L / min, backflush gas flow rate 2 L / min; analyte ion pair parameters are shown in Table 2; Table 2 2. The method for joint detection of multiple antibiotics in a sample to be tested according to claim 1, characterized in that: The stock solution was prepared by weighing 10 target objects in a 50 mL centrifuge tube using a 1 / 100,000 balance, including 21.05 mg of vancomycin, 40.82 mg of daptomycin, 23.04 mg of meropenem, 4.02 mg of linezolid, 4.01 mg of voriconazole, 85.29 mg of cefoperazone, 100 mg of piperacillin, 8.24 mg of levofloxacin, 4.58 mg of moxifloxacin and 10.02 mg of fluconazole, dissolved in 10 mL of DMSO / methanol / water solution (v:v:v=1:10:9), and stored at -80°C.

3. The method for joint detection of multiple antibiotics in a sample to be tested according to claim 1 or 2, characterized in that: The calibration curve and quality control product are prepared as follows: the stock solution is mixed with drug-free blank serum, so that the highest concentrations of vancomycin, meropenem, fluconazole, cefoperazone, linezolid, levofloxacin, piperacillin, moxifloxacin, voriconazole, and daptomycin in the working calibration curve are 99.99 mg / L, 99.99 mg / L, 49.10 mg / L, 400.01 mg / L, 19.90 mg / L, 40.38 mg / L, 480.50 mg / L, 22.67 mg / L, 19.65 mg / L, and 200.02 mg / L, respectively; the other concentration points of the calibration curve are obtained by mixing the highest concentration with blank serum and gradient dilution; The quality control product is prepared as follows: the concentration of vancomycin is 3.81mg / L-35.19mg / L; the concentration of meropenem is 4.46mg / L-40.21mg / L; the concentration of fluconazole is 1.38mg / L-13.44mg / L; the concentration of cefoperazone is 15.26mg / L-146.72mg / L; the concentration of linezolid is 0.96mg / L-8.6mg / L; the concentration of levofloxacin is 1.14mg / L-10.57mg / L; the concentration of piperacillin is 13.49mg / L-125.85mg / L; the concentration of moxifloxacin is 0.79mg / L-7.4mg / L; the concentration of voriconazole is 0.72mg / L-7.21mg / L; the concentration of daptomycin is 10.56mg / L-85.58mg / L To ensure the integrity of the serum at the highest concentration point of the calibration curve and during the preparation of quality controls, the final volume of the total content of water, methanol, and DMSO was kept ≤10%.

4. The method for joint detection of multiple antibiotics in a sample to be tested according to claim 1 or 2, characterized in that: Preparation of the isotope internal standard: the stock solution concentration of the internal standards voriconazole-[13C2, d3], meropenem-[d6], linezolid-[d3], piperacillin-[d5], levofloxacin-[d3] is 1 mg / mL, the stock solution concentration of moxifloxacin-[d4] is 2 mg / mL, and the stock solution concentration of norvancomycin is 40 mg / mL. The concentration of voriconazole-[13C2, d3] and linezolid-[d3] in the internal standard working solution is 0.1 mg / mL, the concentration of meropenem-[d6], piperacillin-[d5], levofloxacin-[d3], moxifloxacin-[d4] is 0.2 mg / mL, and the concentration of norvancomycin is 4 mg / mL, which are mixed in a methanol solution and stored at -80°C before use.

5. The method for joint detection of multiple antibiotics in a sample to be tested according to claim 1 or 2, characterized in that: The sample processing described is as follows: each point of the serum calibration curve and the low, medium and high level quality control products are mixed with the internal standard working solution, the test tube is vortexed and mixed, centrifuged, the supernatant is diluted with 0.1% formic acid water, and then the sample is injected into LC-MS / MS to monitor the reaction of all analytes.

Citation Information

Patent Citations

  • Kit and method for detecting 32 antibiotics based on LC-MS / MS

    CN114965759A

  • LC-MS / MS analysis method for simultaneously detecting nine antibiotics in blood

    CN116087350A

Cited By

  • An enrichment detection method for simultaneously detecting 9 antibiotic drugs in human serum

    CN122754362A